晨光生物: 2025年半年度业绩预告

Performance Forecast - The company expects to achieve a net profit attributable to shareholders of between 202 million yuan and 232 million yuan for the first half of 2025, representing a year-on-year increase of 102.33% to 132.38% [1][2] - The non-recurring gains and losses are estimated to impact the profit by approximately 28 million yuan [2] Revenue and Profit Analysis - The company's revenue for the first half of 2025 is projected to be 3,490.93 million yuan, with a year-on-year growth rate ranging from -0.89% to 7.71% [1] - The net profit after deducting non-recurring gains and losses is expected to be between 174 million yuan and 204 million yuan, showing a year-on-year increase of 117.40% to 154.88% [1] Factors Influencing Performance - The increase in overall performance is attributed to the growth in gross profit from plant-derived products such as chili red, chili extract, and steviol glycosides [1]